All In Biotech

Drug Trial Radar · NCT04529850

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

An Open Label Multi-Center Study of the Effects of GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis Associated With Chemo RT for Locally Advanced, Non-Metastatic Head and Neck Cancer

Last checked: Nov 20, 2026Latest source record: Aug 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Jun 30, 2020

Primary completion

Mar 10, 2021

Study completion Mar 10, 2021

Sponsor

Lead sponsor
Galera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 (IV) when administered in combination with IMRT and cisplatin to up to subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)

Conditions

  • Head and Neck Cancer
  • Oral Mucositis

Interventions

  • Drug: GC4419Drug

    GC4419 60 Minute Infusion

  • Intensity-modulated radiation therapy (IMRT)Radiation

    2.0 to 2.2 Gy daily over 7 weeks

  • CisplatinDrug

    100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent AE'sTime frame: First dose of study medication through the 30 days following the last dose of IMRT, GC4419, or cisplatin (whichever occurs last) which is estimated to be 11 weeks

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst

    Aalst, Belgium

  • AZ Klina

    Brasschaat, Belgium

  • Az Nikolaas

    Sint-Niklaas, Belgium

  • CHR Verviers

    Verviers, Belgium

  • Fakultni Nemocnice Na Bulovce

    Prague, Czechia

  • University Medical Center Schleswig-Holstein

    Kiel, Germany

  • Universitatsklinikum Leipzig AoR

    Leipzig, Germany

  • Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy

    Bydgoszcz, Poland

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie

    Krakow, Poland

  • Szpitale Pomorskie Sp. z o.o.

    Pomorskie, Poland

  • Cancer Center Institute of Oncology

    Warsaw, Poland

  • Complejo Hospitalario Universitario De Santiago De Compostela

    A Coruña, Spain

  • Gurutzetako Unibersitate Ospitalea - Hospital Universitario Cruces - Instituto BioCruces

    Barakaldo, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario de Fuenlabrada

    Fuenlabrada, Spain

  • Institut Catala d'Oncologia de Girona

    Girona, Spain

  • Complejo Hospitalario de Jaen

    Jaén, Spain

  • Hospital Madrid Universitario Sanchinarro (Centro Integral Oncologico Clara Campal)

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Complejo Hospitalario de Navarra (CHN)

    Pamplona, Spain

  • Hospital universitario Virgen del Rocio

    Salamanca, Spain

  • Universidad de Salamanca - Hospital Clinico Universitario

    Salamanca, Spain

  • University Hospital Basel

    Basel, Switzerland

  • University Hospital of Bern, Inselspital

    Fribourg, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.